HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancerSep 29Regulatory decisionAstraZenecaHutchmed
HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer dataSep 24PublicationAstraZenecaHutchmed
HUTCHMED and AstraZeneca report positive Phase III SAFFRON data in EGFR-mutated lung cancerAug 17Clinical readoutAstraZenecaHutchmed
HUTCHMED wins NMPA approval for Orpathys in MET-amplified gastric cancerJul 2Regulatory decisionAstraZenecaHutchmed
Sign inSign in